Investigation of an efficacy of eplerenone combined therapy for hypertensive patients with chronic kidney disease that enough hypotensive effect are not obtained with an angiotensin receptor blocker - Optimal Hypertension Therapy with Aldosterone Blocker Selara (OWASE)

OWASE study Project Office0 个研究点目标入组 200 人开始时间: 2011年7月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Uncontrolled hypertension (systolic blood pressure is equal or more 220 mmHg, or diastolic blood pressure is equal or more 110 mmHg) 2. Unstable angina pectoris 3. Myocardial infarction occurs within 6 months 4. Severe heart failure (NYHA class is equal or more than III) 5. Severe arrhythmia (frequent ventricular or atrial extrasystole, prolonged ventricular tachycardia, atrial tachyarrhythmia, atrial fibrillation, atrial flutter, sick sinus syndrome or atrio-ventricular block) 6. eGFR is less than 36mL/min/1.73m2 7. Severe liver dysfunction or Child-Pugh class score is C 8. Active cancer 9. Serum potassium is equal or more than 5 mEq/L 10. Diabetic patients with microalbuminuria (urinary albumin/creatinine ratio is equal or more than 30mg/gCr) or proteinuria 11. Supplementation of K or administration of K-sparing diuretics 12. Administration of itraconazole, ritonavir or nelfinavir 13. Administration of steroid or immunosuppressant 14. Pregnant, possible to be pregnant 15. Patient who is already treated for study drugs 16. Patients with allergy or contraindication to study drugs 17. Patients that it is impossible to get an agreement 18. Patients who are inadequate by determination of physician in charge

发起方

OWASE study Project Office